Iguratimod API is a pharmaceutical-grade Disease-Modifying Antirheumatic Drug (DMARD) indicated for the treatment of rheumatoid arthritis (RA) and other autoimmune inflammatory disorders. It exerts anti-inflammatory and immunomodulatory effects by suppressing the production of inflammatory cytokines such as TNF-α, IL-1, IL-6, and IL-17, while also inhibiting B-cell immunoglobulin production.
Iguratimod is formulated into oral tablet formulations and is widely used to reduce joint inflammation, slow disease progression, and improve physical function in patients with rheumatoid arthritis.
Manufactured under WHO-GMP-certified facilities, our Iguratimod API offers exceptional purity, stability, and batch-to-batch consistency. Every batch undergoes stringent quality testing and is supplied with complete regulatory documentation, including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and Product Specifications.
Iguratimod API is used in pharmaceutical formulations for the treatment of rheumatoid arthritis and other autoimmune inflammatory diseases.
Iguratimod suppresses inflammatory cytokine production and modulates immune responses, helping reduce joint inflammation and slow disease progression.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation.
Yes. We supply Iguratimod API in commercial quantities with worldwide export support.
Get Bulk Quote via WhatsApp